Analyst picks & changes

Alza Corp.


Elan plc


Hambrecht & Quist analyst D. Larry Smith predicted that the FDA won't take any labeling action on

calcium channel

blockers — several which use delivery technology from AZA or ELN — based on a "flawed" retrospective

Read the full 436 word article

How to gain access

Continue reading with a
two-week free trial.